Press release content from Business Wire. The AP news staff was not involved in its creation.
Gilead Sciences and Gritstone Announce Collaboration Utilizing Gritstone’s Vaccine Platform Technology for HIV Cure
February 1, 2021 GMT
FOSTER CITY, Calif. & EMERYVILLE, Calif. (BUSINESS WIRE) Feb 1, 2021
Gilead Sciences, Inc. (Nasdaq: GILD) and Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, today announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for human immunodeficiency virus (HIV) infection.
Gritstone Oncology CEO Andrew Allen explained how the nascent cancer drug developer caught the attention of the Gates Foundation in developing a potential coronavirus vaccine to slow the emergence of Covid-19 variants.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Gritstone and Genevant Sciences Announce License Agreement for COVID-19 Vaccine
Gritstone Oncology, IncJanuary 20, 2021 GMT Deal provides nonexclusive access to Genevant’s leading LNP technology for use in Gritstone’s self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to initiate in 1Q21 Agreement is the second between the parties since October 2020
EMERYVILLE, Calif. and VANCOUVER, British Columbia and BASEL, Switzerland , Jan. 20, 2021 (GLOBE NEWSWIRE) Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and the industry’s most robust and expansive lipid nanoparticle (LNP) patent estate, today announced an agreement pursuant to whi
Trade Carefully With Soaring Gritstone Oncology The history we are concerned about is the past couple of weeks. Stocks quotes in this article: GRTS, PFE
In his first Executive Decision segment of
Mad Money Wednesday evening, Jim Cramer spoke with Andrew Allen, co-founder, president and CEO of Gritstone Oncology (GRTS) , the biotech applying targeted oncology therapies to develop the second generation of Covid vaccines.
News of positive pre-clinical trial data has sent the stock price soaring.
Allen admitted that he hopes Gritstone s vaccines are never needed on a large scale, but he said they are already starting to see signs that Covid is mutating. Those mutations, he said, may eventually become resistant to the current crop of vaccines that are only just beginning to roll out worldwide.